Peter Riedell
Associate Professor of Medicine · University of Chicago Medical Center
Credentials: · · · · ·
History
Research
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
New England Journal of Medicine · 2022 · 1,350 citations
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nature Medicine · 2022 · 478 citations
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
New England Journal of Medicine · 2023 · 409 citations
32 papers
26 papers
16 papers
- MP
15 papers
14 papers
14 papers
13 papers
13 papers
Clinical trials
- 2024–2032
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
- 2022–2027
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 1, Phase 2
Cellectis S.A.